Meriwether Wealth & Planning’s GSK GSK Stock Holding History

Meriwether Wealth & Planning’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,384	Closed	-$209K	–	132
2025 Q1	$209K	Buy	+5,384	New	+$197K	0.14%	117

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Meriwether Wealth & Planning's GSK Position: Q2 2025 in Review

Meriwether Wealth & Planning sold out of GSK (GSK) in Q2 2025, closing a stake of 5,384 shares — an estimated $209K sold.

Meriwether Wealth & Planning first reported a position in GSK in Q1 2025 and held it in 1 quarter. The position peaked at $209K in Q1 2025. 890 funds tracked by Wall St. Rank hold GSK as of Q2 2025.

Meriwether Wealth & Planning reported no remaining GSK position as of Q2 2025 after selling out during the quarter.
Meriwether Wealth & Planning sold 5,384 GSK shares in Q2 2025, an estimated $209K.
Meriwether Wealth & Planning first reported a position in GSK in Q1 2025 and held it in 1 quarter.
Meriwether Wealth & Planning's GSK position peaked at $209K in Q1 2025.
890 funds tracked by Wall St. Rank held GSK as of Q2 2025.

Based on Meriwether Wealth & Planning's 13F filing for Q2 2025, filed 11 Jul 2025.